静脉VSV-hIFNβ-NIS治疗晚期或复发性子宫内膜癌的I期试验
该I期试验纳入21例IV期或复发性子宫内膜癌患者,接受单次静脉输注表达hIFNβ和NIS的VSV,采用标准3+3剂量递增,计划5个剂量水平。因生产限制未达DL5,MTD未确定;常见治疗相关不良事件为短暂血液学毒性、肝酶升高和CRS。2例疾病稳定至少6个月;后续接受ICI治疗的15例中4例获持久SD,中位随访40.4个月。
要点
- 静脉VSV-hIFNβ-NIS在晚期或复发性子宫内膜癌中安全性可接受,MTD未达到。
- 2例患者在接受VSV-hIFNβ-NIS后疾病稳定至少6个月。
- 后续ICI治疗的15例中4例获持久SD,中位随访40.4个月。
核心结论
- 静脉VSV-hIFNβ-NIS在晚期或复发性子宫内膜癌患者中安全性可接受,值得进一步研究,尤其与免疫检查点阻断联合。
研究设计与样本
- I期试验,采用标准3+3剂量递增,计划5个剂量水平,纳入最大肿瘤直径≤5 cm的IV期或复发性子宫内膜癌患者,单次静脉输注VSV-hIFNβ-NIS。
- 主要终点为确定最大耐受剂量(MTD);次要终点包括药代动力学、药效动力学、肿瘤反应和免疫相关指标;事后探索性分析评估后续ICI治疗的临床反应。
主要发现
- DL2的1例患者发生与细胞因子释放综合征(CRS)相关的3级脱水,1例发生短暂4级无症状淋巴细胞减少,促使方案修改DLT定义。
- DL4的6例患者中1例发生符合DLT标准的3级谵妄。
- 因研究药物生产限制,剂量递增至DL5不可行,MTD未达到。
- 最常见的治疗相关不良事件为短暂血液学毒性、肝酶升高和CRS。
- 第29天时8例患者疾病进展(PD),1例在第29天前因PD进入临终关怀;2例患者在VSV-hIFNβ-NIS后疾病稳定至少6个月;后续接受ICI治疗的15例患者中4例获持久SD,中位随访40.4(95%CI 30.4-未达到)个月。
临床怎么用
- 静脉VSV-hIFNβ-NIS可作为晚期或复发性子宫内膜癌患者的一种安全性可接受的试验性治疗选择。
- 后续联合免疫检查点抑制剂治疗值得进一步研究。
局限性
- 因研究药物生产限制,未能进行DL5剂量递增,MTD未确定。
- 样本量小(21例),后续ICI治疗分析为事后探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We report the results of a Phase I trial of intravenous (IV) vesicular stomatitis virus (VSV) engineered to express human interferon beta (hIFNβ) and thyroidal sodium iodide symporter (NIS) in patients with stage IV or recurrent endometrial cancer (EC). METHODS: Eligible patients with stage IV or recurrent EC with largest tumor diameter ≤ 5 cm were enrolled and received a single IV infusion of VSV-hIFNβ-NIS in a standard '3 + 3' dose escalation. Five dose-levels were planned. Primary endpoint was determination of the maximum tolerated dose (MTD). Secondary endpoints included pharmacokinetics, pharmacodynamics, tumor response, and immune correlates. An exploratory post-hoc analysis evaluated clinical responses to subsequent immune checkpoint inhibitor (ICI)-based therapies. RESULTS: From 9/15/2017-1/10/23, 21 eligible patients were treated. One patient at DL2 experienced grade 3 dehydration associated with cytokine release syndrome (CRS) and one experienced transient grade 4 asymptomatic lymphopenia, prompting protocol modification of the DLT definition. One of six patients at DL4 experienced grade 3 delirium meeting DLT criteria. Dose escalation to DL5 was not feasible because of investigational agent production limitations; MTD was not reached. The most common treatment related AEs were transient hematologic toxicities, liver enzyme elevations, and CRS. At day 29, 8 patients had progressive disease (PD); 1 entered hospice due to PD before day 29. Two patients had stable disease for at least 6 months following VSV-hIFNβ-NIS. Of the 15 patients who received subsequent ICI-based therapy following VSV-hIFNβ-NIS, 4 had durable SD with a median follow up of 40.4 (95% CI 30.4-not reached) months. CONCLUSIONS: IV VSV-hIFNβ-NIS had an acceptable safety profile in patients with advanced or recurrent EC. Further investigation of VSV-hIFNβ-NIS, particularly in combination with immune checkpoint blockade, is warranted.
引用
- Warring SK, Peng KW, Atherton PJ, et al. A phase I trial of intravenous vesicular stomatitis virus expressing thyroidal sodium iodide symporter (NIS) and human interferon beta (hIFNβ) in metastatic or recurrent endometrial cancer. Gynecol Oncol. 2026. PMID: 42987473. doi:10.1016/j.ygyno.2026.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。